Persbericht

19/09/2018 ASIT biotech presents its 2018 half-year results and provides an update on its clinical programs until end-2019 (19.9.2018
19/09/2018 MONTEA-KENNISNKENNISNAME AANKOOP AANDELEN MONTEA DOOR AANDEELHOUDERS (19.9.2018)
18/09/2018 ENGIE, the leading utility of the Dow Jones Sustainability Index World (18.9.2018)
18/09/2018 Montea zal via sale-and-rent back formule een terrein van 47,9 ha in Tiel (NL) verwerven (18.9.2018)
18/09/2018 Miko-halfjaarresulaten (18.9.2018)
18/09/2018 argenx announces launch of proposed public offering in the United States (18.9.2018)
14/09/2018 ABO-Group - Halfjaarcijfers 2018 (14.9.2018)
17/09/2018 Oxurion to present further scientific findings supporting therapeutic potential of THR-317 & THR-687 as promising new therapies for Diabetic Eye Disease (17.9.2018)
17/09/2018 Orange-Google Chromecast now available for Orange Love customers (17.9.2018)
17/09/2018 ATENOR-AKKOORD OVER DE VERKOOP VAN NAOS IN LUXEMBURG (17.9.2018)
17/09/2018 Leasinvest Real Estate Comm. VA-Leasinvest Real Estate verwerft kantoorgebouw op toplocatie in Europese wijk te Brussel (BE) & sluit belangrijke verhuring af in Cloche d’Or (LU) (14.9.2018)
17/09/2018 WDP realiseert acquisitie van bijkomende site te Zellik via kapitaalverhoging van 5 miljoen euro (17.9.2018)
17/09/2018 argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia (17.9.2018)
14/09/2018 PCB-Openbaar uitkoopbod aan minderheidsaandeelhouders (14.9.2018)
14/09/2018 Acacia Pharma-Positive BARHEMSY Phase 3 Treatment Data Published in Anesthesia & Analgesia (14.9.2018)
14/09/2018 Bone Therapeutics SA announces final results from Phase I/IIA ALLOB delayed-union fracture study (14.9.2018)
13/09/2018 Agfa wijst toenaderingspoging Kanteron Systems af (13.9.2018)
13/09/2018 Telenet voor de zesde maal leider in duurzaamheid binnen de Dow Jones Sustainability Index (13.9.2018)
13/09/2018 Intrervest offices and warehouses : transparantie mededeling (13.9.2018)
13/09/2018 UCB-Data Presented at EADV 2018 Further Demonstrate the Value of CIMZIA and Bimekizumab (13.9.2018)